GlassScriptPhysician profile
Meghan Smith
NPI 1093350464
$2,955.55
in general payments reported to CMS, 2019-2025
33 companies · $876 in 2025
The $876 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $718 · 2023: $302 · 2024: $502 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,679.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $890.43 | 2021-2025 | |
| Glaxosmithkline, LLC. | $361.97 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.91 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $203.81 | 2024-2025 | Tremfya, Stelara |
| Lilly USA, LLC | $134.99 | 2021-2025 | Omvoh |
| Ardelyx, INC. | $107.68 | 2024-2025 | Ibsrela |
| Actelion Pharmaceuticals US, INC. | $105.07 | 2022 | |
| Genzyme Corporation | $91.86 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.21 | 2022-2025 | Eohilia, Entyvio |
| Astrazeneca Pharmaceuticals LP | $71.81 | 2022 | |
| Novo Nordisk INC | $70.39 | 2021-2025 | Wegovy |
| Qol Medical, LLC | $65.63 | 2023-2024 | Sucraid, Sucraid |
| Amgen INC. | $45.48 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $42.74 | 2022 | |
| Merck Sharp & Dohme LLC | $35.90 | 2024 | Dificid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.37 | 2021 | |
| Madrigal Pharmaceuticals | $34.18 | 2024 | Resmetirom |
| Daiichi Sankyo INC. | $34.16 | 2021-2024 | Vanflyta |
| Pfizer INC. | $34.03 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $33.68 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $26.21 | 2025 | Iqirvo |
| Sunovion Pharmaceuticals INC. | $22.51 | 2021 | |
| Insmed, INC. | $21.01 | 2022 | |
| Evoke Pharma, INC. | $19.47 | 2024 | |
| Inogen, INC. | $18.61 | 2022 | |
| United Therapeutics Corporation | $18.42 | 2022 | |
| Aimmune Therapeutics, INC. | $18.37 | 2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $18.29 | 2025 | |
| Amarin Pharma, INC. | $17.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.36 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $14.22 | 2023 | Linzess |
| Janssen Pharmaceuticals, INC | $13.43 | 2021 | |
| Baxter Healthcare | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.